The Hyperintense study: Assessing the effects of induced blood pressure increase and decrease on MRI markers of cerebral small vessel disease: Study rationale and protocol

Esther Janssen1,2, Annemieke ter Telgte3, Esmée Verburgt1,2, Joost JA de Jong4, José P Marques2, Roy PC Kessels2,5,6, Walter H Backes4, Marnix C Maas7, Frederick JA Meijer7, Jaap Deinum8, Niels P Riksen8, Anil M Tuladhar1,2 and Frank-Erik de Leeuw1,2

Abstract

Background: Neuroimaging markers of cerebral small vessel disease (SVD) are common in older individuals, but the pathophysiological mechanisms causing these lesions remain poorly understood. Although hypertension is a major risk factor for SVD, the direct causal effects of increased blood pressure are unknown. The Hyperintense study is designed to examine cerebrovascular and structural abnormalities, possibly preceding SVD, in young adults with hypertension. These patients undergo a diagnostic work-up that requires patients to temporarily discontinue their antihypertensive agents, often leading to an increase in blood pressure followed by a decrease once effective medication is restarted. This allows examination of the effects of blood pressure increase and decrease on the cerebral small vessels.

Methods: Hyperintense is a prospective observational cohort study in 50 hypertensive adults (18–55 years) who will temporarily discontinue antihypertensive medication for diagnostic purposes. MRI and clinical data is collected at four timepoints: before medication withdrawal (baseline), once antihypertensives are largely or completely withdrawn (T = 1), when patients have restarted medication (T = 2) and reached target blood pressure and 1 year later (T = 3). The 3T MRI protocol includes conventional structural sequences and advanced techniques to assess various aspects of microvascular integrity, including blood-brain barrier function using Dynamic Contrast Enhanced MRI, white matter integrity, and microperfusion. Clinical assessments include motor and cognitive examinations and blood sampling.

Discussion: The Hyperintense study will improve the understanding of the pathophysiological mechanisms following hypertension that may cause SVD. This knowledge can ultimately help to identify new targets for treatment of SVD, aimed at prevention or limiting disease progression.

Keywords

Small vessel disease, hypertension, blood brain barrier, DCE-MRI, cerebral blood flow, diffusion tensor imaging

Date received: 22 March 2022; accepted: 24 April 2022

1Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
2Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, The Netherlands
3VASCage GmbH, Research Centre on Vascular Ageing and Stroke, Innsbruck, Austria
4School for Mental Health & Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands
5Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands
6Department of Medical Psychology and Radboudumc Alzheimer Center, Radboud University Medical Center, Nijmegen, The Netherlands
7Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
8Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

Corresponding author:
Frank-Erik de Leeuw, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Email: Frankerik.deleeuw@radboudumc.nl
Background

Cerebral small vessel disease (SVD) is an umbrella term covering a variety of pathologies that affect the small arteries, arterioles, and capillaries in the brain. SVD can be clinically covert, but is associated with cognitive decline, dementia, and disturbances in gait and mood. Moreover, most hemorrhagic strokes and a fourth of all ischemic strokes are caused by SVD.

Small vessel pathology cannot be visualized in vivo with standard 1.5 or 3T Magnetic Resonance Imaging (MRI). SVD is therefore usually defined by tissue alterations on MRI thought to be a consequence of small vessel pathology, such as white matter hyperintensities (WMH), lacunes, and microbleeds. However, these MRI markers are likely the result of long ongoing pathological processes and studying them provides limited insights into their (early) pathogenesis. Endothelial dysfunction is hypothesized to play a key role in the pathophysiology of SVD and may explain the various pathologies seen in SVD patients, including loss of integrity of the Blood Brain Barrier (BBB), vessel wall stiffening, impairments in vasodilation, reduced cerebral blood flow, and increased inflammation. The relation between these pathological processes, the order in which they occur and the role they play in the etiology of SVD remains largely unknown.

To advance our understanding of SVD etiology and progression, research in young- and middle-aged adults at risk or with early-stage SVD is crucial. Hypertension is the most established risk factor for SVD, but evidence is based on prospective and cross-sectional studies. Higher blood pressure in midlife is shown to lead to higher SVD burden and smaller brain volumes at later age. Moreover, the presence of cardiovascular risk factors, including hypertension, at a young age (18–40 years), is associated with changes in vessel morphology (i.e. vessel density and vessel caliber) and higher WMH volume. This suggests that small vessel changes precede end-stage MRI markers and the accompanying clinical symptoms for decades, but the underlying mechanisms are unknown. In addition, the causal relation with hypertension is predominantly based on prospective cohort studies and trials that have shown slower SVD progression among those with lower blood pressure or active treatment with anti-hypertensives, but no studies have examined the actual effect of increasing blood pressure on MRI markers of SVD.

In this paper we describe the protocol of the Hyperintense study. We will apply an advanced MRI protocol to examine early functional and (micro)structural changes in young- and middle-aged adults with hypertension, the most important cardiovascular risk factor of SVD. Specifically, we will examine the effects of blood pressure increases in patients with hypertension who undergo a routine diagnostic work up which includes temporary withdrawal of their antihypertensives, followed by subsequent decrease after reinstatement of therapy. The design of this study, that is, temporal withdrawal of antihypertensive drugs in patients with refractory hypertension, allows assessment of the pathological mechanisms following blood pressure increase. At four time-points, advanced MRI sequences will be applied to probe potential changes in BBB integrity, microvascular perfusion, microstructural integrity, and functional connectivity.

Methods

Study population and design

Patients with hypertension (n = 50) will be recruited at the outpatient clinic of the Department of Internal Medicine of the Radboud University Medical Center (Radboudumc), which is a national referral center for patients with complex hypertension. Approximately 120 patients aged 18–55 years with hypertension are referred to the Radboudumc annually. These patients are often referred by general practitioners or other hospitals when blood pressure is not well-controlled (>140/90 mmHg) despite the use of three or more antihypertensive drugs or when there is clinical suspicion for secondary forms of hypertension. To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs interfere with this ratio, patients often have to discontinue antihypertensive drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine) according to local protocols. Medication has to be stopped for at least 4 weeks (for mineralocorticoid receptor antagonists) or 2 weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly, and blood pressure levels drop again. This diagnostic protocol with temporary withdrawal of antihypertensive medication has been proven to be safe.

Antihypertensive medication is discontinued in approximately 50% of patients referred to Radboudumc. We expect that at least 30% of these patients will be willing to participate in our study, making it feasible to include 50 patients within the planned 2.5 years. All participants will be asked to provide written informed consent. This study has been approved by the medical ethics committee region Arnhem-Nijmegen.

Inclusion criteria

1. Age of 18–55 years
2. Antihypertensive drug treatment for hypertension
3. Temporary antihypertensive medication withdrawal as part of clinical diagnostic routine
Exclusion criteria

Subjects will be excluded if they meet any of the following criteria:

1. A history of an ischemic or hemorrhagic stroke or transient ischemic attack (TIA). This is based on self-report and subsequent verification of available medical documentation.
2. Conditions leading to similar appearance of MRI markers as SVD, including:
   a. Large-artery disease, defined as stenosis >50% in the internal carotid artery or vertebral artery based on ultrasound collected at baseline and medical records
   b. Cardioembolism, defined as atrial fibrillation or other high risk cardioembolic conditions (based on medical history)
   c. Vasculitis
3. Major neurological/psychiatric diseases or other diseases that prevent long-term follow-up
4. Contraindications for 3T MRI
   a. Renal insufficiency (eGFR <30 ml/min, insufficient kidney function to receive gadolinium-based contrast agent for DCE-MRI)
   b. Pregnancy
5. Inability to give informed consent.

Study visits

Participants will be requested to complete four study visits, combined with routine visits to the outpatient clinic when possible (Figure 1). The baseline measurement is conducted just before antihypertensive medication is withdrawn ($T_0$). The second study visit ($T_1$) will take place approximately 2–6 weeks after antihypertensive medication withdrawal when blood pressure is increased. $T_2$ is scheduled within 2–4 months once patients have reached their target blood pressure and blood pressure is stable. The final study visit takes place approximately 1 year after $T_2$ ($T_3$). After the final study visit, long-term future incident clinical events will be monitored by contacting the GP or treating physician of the participants. Table 1 shows the data that will be collected at each study visit.

Imaging protocol

During each study visit, a brain MRI scan will be performed on a 3T MRI system (MAGNETOM PrismaFit, Siemens Healthcare, Erlangen, Germany) using a 20 channel head-neck coil. The total imaging protocol will take approximately 75 min and includes the following sequences: 3D T1-weighted MP2RAGE, Fluid Attenuated Inversion Recovery (FLAIR), susceptibility-weighted imaging (SWI), multi-shell Diffusion Weighted Imaging (DWI), resting-state functional MRI (rs-fMRI), Intravoxel Incoherent Motion (IVIM), and Dynamic Contrast Enhanced (DCE) MRI. In addition, a B0 field map and a diffusion-weighted sequence with reversed phase-encoding direction were acquired for distortion correction of DWI, IVIM, and rs-fMRI scans. Acquisition parameters for all sequences are shown in Supplemental Table 1. DCE-MRI consists of successive slow, fast, and slow T1-weighted saturation recovery spoiled GRE pulse sequences. Gadobutrol contrast agent (0.1 mmol/kg) will be injected at a 3 ml/s rate followed by a 20 ml saline flush during the fast sequence. This macrocyclic agent is shown to be more stable than other gadolinium-base contrast agents and can therefore safely be used for multiple MRI assessments.

MRI processing and analysis

Structural MRI measures

MRI markers of SVD. Conventional MRI markers of SVD, such as WMH, lacunes, microbleeds, enlarged perivascular spaces, and recent infarcts will be examined following the STRIVE guidelines. WMH volume will be calculated using an in-house developed and validated technique that has previously been described.

DWI. Diffusion-weighted images will be processed according to a previously described protocol. In short, images will be visually inspected to exclude major artifacts. The following preprocessing steps will be applied: denoising, removal of Gibbs artifacts and correction for head motion, susceptibility-induced distortions, and eddy current-induced distortions. To do this we will use the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library (FSL; v5.0, topup, eddy) and MRtrix3 (mrtrix.org/, dwidenoise, mrdegbbs). BET (FSL) is used to extract brain tissue, after which the diffusion tensor metrics (FA and MD) will be calculated using DTIFIT (FSL).

Next to these common DTI-derived measures, the Peak Width of Skeletonized Mean Diffusivity (PSMD) will be calculated. PSMD is based on skeletonization and histogram analysis and is calculated as the difference between the 95th and 5th percentiles of MD values within the masked skeleton. This approach is suggested to improve detection of subtle diseases in the brain.

Functional MRI measures

IVIM. IVIM is a DWI-technique that is used to study both microvascular perfusion and changes in microstructural tissue properties, which is especially useful in SVD research since both are impaired in this disease. Processing of IVIM images has been previously described. In short, preprocessing steps will include visual inspection of image quality, distortion corrections and head motion correction. To model the diffusion-attenuated signal, a two-compartment diffu-
tion model is used that describes vascular and nonvascular compartments. Fitting of the model will be performed on a voxel-by-voxel basis using a previously described two-step method. Measures derived from this model include: the perfusion volume fraction $f$, the diffusion coefficient of parenchymal water $D$, and the pseudodiffusion coefficient of circulating blood $D^*$. Furthermore, $fD^*$ is a blood perfusion related measure that will be calculated.

**DCE-MRI.** DCE-MRI images will be processed according to previously described protocol by performing pharmacokinetic modeling and histogram analyses. Images are segmented into white and gray matter using the $T_1$-weighted image and WMH are segmented on FLAIR images. After coregistration of $T_1$-weighted images and FLAIR, Normal Appearing White Matter (NAWM), WMH, cortical gray matter, and deep gray matter are selected as regions of interest (ROI).

To calculate the concentration of the contrast agent in tissue, the relative signal enhancement and $T_1$ maps derived from the MP2RAGE sequence will be used. The vascular input function used to calculate the contrast concentration
in blood plasma will be derived from the superior sagittal sinus.\textsuperscript{23} The slope and intercept of the graphical Patlak model will be used to calculate the leakage rate (transfer constant \(K_t\)).\textsuperscript{24} A histogram is created for the \(K_t\) values in each ROI in a voxel-wise manner. Two measures to quantify BBB leakage are derived from these histograms: the mean transfer constant \(K_t\) as a measure of leakage rate and the area under the histogram curve as a measure of tissue volume of leaking microvessels (\(V_l\)). These measures will be calculated for all ROIs. \(T_1\) values in these ROIs will be computed at the individual level to evaluate the interaction between hypertension and \(T_1\), a marker of water mobility.

**Resting-state fMRI.** Processing of resting-state functional MRI (rs-fMRI) includes the following steps: removal of artifacts, correction for slice time and head motion, coregistration of functional and structural images, normalization of subject brain to Montreal Neurological Institute (MNI) space and spatial filtering. Graph theory will be used to examine functional brain networks using a previously described protocol.\textsuperscript{25} In short, 264 functional areas will be used as network nodes in the cerebral cortex, subcortical structures, and cerebellum.\textsuperscript{26} We will define five functional networks: a global brain network, the default mode network, the fronto-parietal task control network, the somatosensory-motor network of the hand, and the visual network.\textsuperscript{25} For these networks, we will calculate the weighted global efficiency and the weighted clustering coefficient, since these measures have previously been shown to be sensitive to structural network abnormalities in SVD patients.\textsuperscript{27}

**Primary outcomes**

Primary outcomes of this study will be the changes in MRI outcomes after withdrawal of antihypertensive medication (highest blood pressure) and subsequent restart (lowest blood pressure). MRI outcomes include WMH volume, PSMD, BBB leakage rate and volume, IVIM outcomes (\(D, fD^*\)), PSMD, network global efficiency, and clustering coefficients and are described in more detail in the “Imaging Protocol” section.

Secondary study outcomes include:

- Effects of antihypertensive medication withdrawal and restart on cognitive and motor functioning
- Baseline associations between cardiovascular risk factors and MRI markers of cerebral structure and vascular functioning
- Association between circulating markers of inflammation, including cytokines and chemokines, measured at \(T=1\) and blood pressure and brain MRI parameters
- Changes in MRI parameters of brain structure and vascular function at 1.5-year follow-up

- Number of future incident clinical events. This includes all-cause mortality, death due to vascular causes, non-fatal strokes (ischemic and haemorrhagic), and TIAs.

**Cognitive assessments**

At baseline, \(T=2\) and \(T=3\) patients will undergo a 60-min cognitive assessment covering six domains: processing speed, attention, executive functioning, verbal memory, working memory, and psychomotor functioning (Supplemental Table 2). All administered tests are validated and widely used. To minimize intra-individual variability, we use standardized tests with high test-retest reliability. Parallel versions will be used to take task-specific practice effects into account. Furthermore, participants will perform the Alertness subtask of the Test of Attentional Performance on a laptop during each study visit. The Alertness subtask is a sensitive test for processing speed and attention, during which participants have to press a button as quickly as possible then a target stimulus is shown.\textsuperscript{28}

**Motor functioning**

Gait speed (m/s) will be determined over a 6-m distance during each study visit to examine motor functioning. Gait and balance of participants will be assessed using the Timed Up & Go Test, measuring the time a participant needs to get up from a chair, walk 3 m, turn around, and sit back down.\textsuperscript{29}

**Questionnaires**

A structured questionnaire will be used at baseline to assess demographic data, medical history and lifestyle behavior (including smoking, alcohol consumption, and drug use). Educational level is determined using a seven-point Dutch rating scale, the Verhage scale.\textsuperscript{30} Medical history includes age of hypertension onset and medication use. At each follow-up visit, changes in medication use and lifestyle behavior, and incident clinical events are assessed.

**Blood sampling**

Blood will be collected at \(T=1\) and \(T=2\) to determine levels of circulating inflammatory markers, such as cytokines after overnight fasting. We will collect 45 ml of blood (20 ml serum, 10 ml EDTA plasma, 9 ml citrate plasma, and 6 ml blood for DNA isolation). Samples will be stored in the Hyperintense BioBank at the Radboudumc for future analyses.

**Physical examination**

We will measure height and weight and calculate the Body Mass Index (BMI). Blood pressure will be measured three times while participant is in seated position.
Sample size calculation
Because the effects of blood pressure increase and decrease on MRI outcomes assessed here have never been examined, there is no information available about the size of these possible effects. A formal sample size calculation is therefore not feasible. Instead, we based our sample size on the number of patients referred to the Radboudumc annually that are eligible for participation in this study within the limited time period of 2.5 years.

Statistical analysis
To analyze primary outcome measures, MRI outcomes at different timepoints will be compared. MRI outcomes are discussed in the imaging analysis section and include: WMH volume, PSMD, BBB leakage rate, BBB leakage volume, IVIM outcomes, FA, MD, network global efficiency, and clustering coefficients. All outcome measures are continuous measures and data will be log-transformed in case of non-normality. We assume a linear (or parametric) relationship between blood pressure and MRI parameters and will therefore run linear mixed models, including all time points. These will be adjusted for age, sex, education, and other conventional MRI markers of SVD. We will not correct for multiple analysis since different MRI measures probe different aspects of the brain in terms of brain structure, physiology, and function. Missing data will be described in our scientific reports.

To examine the association between changes in blood pressure and cognitive and motor functioning, individual cognitive test scores will be adjusted to $Z$-scores using available normative data, adjusting for age, sex, and educational levels when possible. The association between blood pressure and incident clinical events will be investigated using Cox proportional hazard analyses, adjusted for age, sex, education, and SVD MRI markers where appropriate.

Discussion
Little is known about the pathophysiological mechanisms underlying SVD. Research into SVD pathogenesis is hampered by difficulties with visualizing the smallest cerebral vessels with conventional MRI, allowing only the detection of end-stage disease cerebral lesions. Most of the knowledge about SVD is derived from studies conducted in individuals with end-stage disease cerebral lesions. Most of the knowledge about SVD is derived from studies conducted in individuals older than 60 years in whom SVD most likely has become irreversible tissue damage, are needed. The Hyperintense study is the first serial MRI study designed to examine the effects of changes in blood pressure on cerebral microvascularity in young- and middle-aged adults with hypertension, the strongest risk factor for SVD.1

One of the main strengths of this study is the unique design that includes induced hypertension due to temporary withdrawal of antihypertensive medication, followed by blood pressure lowering due to medication restart as part of routine clinical practice, without the need for an intervention study. This design allows analysis of the effects of both increases as well as decreases in blood pressure. Previous studies have examined the effects of blood pressure lowering on SVD measures, but the effects of blood pressure increase have never been studied.35 Furthermore, we combine several advanced MRI techniques to examine early microvascular changes. We use DCE-MRI to examine BBB integrity, which is associated with clinical and imaging features of SVD.34 Since both microstructural integrity and cerebral perfusion are suggested to be diminished in SVD patients, we use multi-shell DWI and IVIM to examine this simultaneously.17 We also use rs-fMRI to examine functional connectivity since (micro)structural damage in SVD patients can lead to disturbed connectivity both between and within brain networks.27 These MRI techniques allow analysis of early pathological mechanisms and the order in which they occur before MRI markers of SVD become visible. Another strength of this study is that the extensive amount of cognitive, motor, and biobank data that is collected in a structured and standardized way. MRI outcomes can therefore be linked to cognitive functioning, measured by tests that are widely accepted and shown to be sensitive to SVD-related brain changes. Assessment of circulating inflammatory markers will help identify ongoing inflammatory responses that may play a central role in SVD pathogenesis.35 We expect the external validity of this study to be high. Since the patients included in this study are highly likely to develop SVD later in life, abnormalities in vascular functioning observed here are presumably also present in other populations at risk of SVD. Findings of this study will therefore have implications for treatment optimization in patients at risk of cerebrovascular damage; reaching conventional target blood pressure may not be sufficient and additional treatment to further lower blood pressure or reduce inflammation and BBB leakage can have beneficial effects on clinical outcomes.

In conclusion, the Hyperintense study is a unique serial MRI project that has the potential to further unravel the association between early-life hypertension and SVD. Although hypertension is considered a main risk factor for developing SVD, it remains unknown how hypertension exerts an effect on brain structure and vascular function. This study will help to identify early-life pathological mechanisms of SVD caused by hypertension. Improved understanding of the pathological mechanisms driving SVD pathogenesis and progression will contribute to identification of new targets for treatment.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
**Funding**
The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Informed consent**
All participants give written informed consent before study participation.

**Ethical approval**
This study has been approved by the committee on Research involving Human Subjects, region Arnhem-Nijmegen (Commissie Mensgebonden Onderzoek – CMO, region Arnhem-Nijmegen).

**Guarantor**
FEdL.

**Contributorship**
EJ wrote the first draft of this manuscript, and is involved in patient recruitment and data analysis. FEdL, AtT, and AMT were involved in protocol development and gaining ethical approval. RPCK was involved in selecting the neuropsychological tests and their analyses. All authors were involved in designing aspects of the study related to his/her field or assessment of the data. EV is involved in patient recruitment. All authors revised the manuscript and approved the final version before publication.

**ORCID iDs**
Esther Janssen https://orcid.org/0000-0003-4483-8705
Frederick Jan Anton Meijer https://orcid.org/0000-0001-5921-639X

**Supplemental material**
Supplemental material for this article is available online.

**References**

1. Wardlaw JM, Smith C and Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol* 2019; 18: 684–696.
2. Wardlaw J, Smith C and Dichgans M. Mechanisms underlying sporadic cerebral small vessel disease: insights from neuroimaging. *Lancet Neurol* 2013; 12: 483–497.
3. Williamson JD, Pajewski NM, Auchus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. *J Am Med Assoc* 2019; 321: 553–561.
4. Lane CA, Barnes J, Nicholas JM, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. *Lancet Neurol* 2019; 18: 942–952.
5. Williamson W, Lewandowski AJ, Forkert ND, et al. Association of cardiovascular risk factors with MRI indices of cerebrovascular structure and function and white matter hyperintensities in young adults. *JAMA* 2018; 320: 665–673.
6. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. *Hypertension* 2002; 40: 897–902.
7. Beeflink MM, van der Sande NG, Bots ML, et al. Safety of temporary discontinuation of antihypertensive medication in patients with difficult-to-control hypertension. *Hypertension* 2017; 69: 927–932.
8. Jellescu IO, Leppert IR, Narayanan S, et al. Dual-temporal resolution dynamic contrast-enhanced MRI protocol for blood-brain barrier permeability measurement in enhancing multiple sclerosis lesions. *J Magn Reson Imaging* 2011; 33: 1291–1300.
9. European Medicines Agency. EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. *EMA website*, https://www.ema.europa.eu/en/news/emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans (2017, accessed 22 April 2022).
10. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013; 12: 822–838.
11. Ghafoorian M, Karssemeijer N, van Uden IW, et al. Automated detection of white matter hyperintensities of all sizes in cerebral small vessel disease. *Med Phys* 2016; 43: 6246–6258.
12. Konieczny MJ, Dewenter A, Ter Tielge A, et al. Multi-shell diffusion MRI models for white matter characterization in cerebral small vessel disease. *Neurology* 2021; 96: E698–E708.
13. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. *Neuroimage* 2004; 23 Suppl 1: S208–S219.
14. Tournier JD, Smith R, Raffelt D, et al. MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation. *Neuroimage* 2019; 202: 116137.
15. Baykara E, Gesierich B, Adam R, et al. A novel imaging marker for small vessel disease based on skeletonization of white matter tracts and diffusion histograms. *Ann Neurol* 2016; 80: 581–592.
16. Low A, Mak E, Stefaani JD, et al. Peak width of skeletonized mean diffusivity as a marker of diffuse cerebrovascular damage. *Front Neurosci* 2020; 14: 238.
17. Wong SM, Zhang CE, van Buuse FC, et al. Simultaneous investigation of microvasculature and parenchyma in cerebral small vessel disease using intravoxel incoherent motion imaging. *Neuroimage Clin* 2017; 14: 216–221.
18. Le Bihan D, Breton E, Lallemant D, et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. *Radiology* 1988; 168: 497–505.
19. Federau C, O’Brien K, Meuli R, et al. Measuring brain perfusion with intravoxel incoherent motion (IVIM): initial clinical experience. *J Magn Reson Imaging* 2014; 39: 624–632.
20. Zhang CE, Wong SM, Uiterwijk R, et al. Intravoxel incoherent motion imaging in small vessel disease: microstructural integrity and microvascular perfusion related to cognition. *Stroke* 2017; 48: 658–663.
21. Kerkhofs D, Wong SM, Zhang E, et al. Blood-brain barrier leakage at baseline and cognitive decline in cerebral small vessel disease: a 2-year follow-up study. *GeroScience* 2021; 43: 1643–1652.
22. Larsson HBW, Courirvad F, Rostrup E, et al. Measurement of brain perfusion, blood volume, and blood-brain barrier
permeability, using dynamic contrast-enhanced $T_1$-weighted MRI at 3 tesla. Magn Reson Med 2009; 62: 1270–1281.

23. Lavini C and Verhoeff JJC. Reproducibility of the gadolinium concentration measurements and of the fitting parameters of the vascular input function in the superior sagittal sinus in a patient population. Magn Reson Imaging 2010; 28: 1420–1430.

24. Patlak CS and Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584–590.

25. Gesierich B, Tuladhar AM, Ter Telgte A, et al. Alterations and test-retest reliability of functional connectivity network measures in cerebral small vessel disease. Hum Brain Mapp 2020; 41: 2629–2641.

26. Power JD, Cohen AL, Nelson SM, et al. Functional network organization of the human brain. Neuron 2011; 72: 665–678.

27. Lawrence AJ, Tozer DJ, Stamatakis EA, et al. A comparison of functional and tractography based networks in cerebral small vessel disease. NeuroImage Clin 2018; 18: 425–432.

28. Zimmermann P and Fimm B. A test battery for attentional performance. In: Leclercq M and Zimmermann P (eds) Applied neuropsychology of attention. New York, NY: Psychology Press, 2002, pp.110–151.

29. Podsiadlo D and Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142–148.

30. Verhage F. Intelligente en leeftijd: onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar. Assen: Van Gorcum, 1964.

31. de Vent NR, Agelink van Rentergem JA, Schmand BA, et al. Advanced Neuropsychological Diagnostics Infrastructure (ANDI): a normative database created from control datasets. Front Psychol 2016; 7: 1601.

32. Smith A. Symbol Digit Modalities Test; Handleiding. Amsterdam, Netherlands: Hogrefe Publishing. 2010.

33. Nasrallah IM, Pajewski NM, Auchus AP, et al. Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA 2019; 322: 524–534.

34. Thrippleton MJ, Backes WH, Sourbron S, et al. Quantifying blood-brain barrier leakage in small vessel disease: review and consensus recommendations. Alzheimers Dement 2019; 15: 840–858.

35. Low A, Mak E, Rowe JB, et al. Inflammation and cerebral small vessel disease: a systematic review. Ageing Res Rev 2019; 53: 100916.